EGFR and non-small cell lung carcinoma: Ataxia–telangiectasia mutations (ATMs) may also define a specific subset of NSCLC associated with Kirsten rat sarcoma virus (KRAS) mutations, increased TMB, decreased tumor protein P53 (TP53) and EGFR coexistence, and potentially increased sensitivity to combined therapy of ICIs and chemotherapy [111].